UNSPSC 51401539: Motrazepam

This classification denotes an anxiolytic with the molecular formula C17H15N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 36YG4ZMR69, chemically known as 2,3-dihydro-1-(methoxymethyl)-7-nitro-5-phenyl-1h-1,4-benzodiazepin-2-on but generally known as motrazepam, which bears US NIH Compound Identifier 65764. European Medicines Agency schedules Motrazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09076MIG.

UNSPSC 51401539 Motrazepam is a Commodity code nominally designated for a specific pharmaceutical product, but the recent state and local opportunities posted under this code show no active solicitations for motrazepam itself. Instead, the code has been applied to three broadly divergent pharmaceutical and pharmacy-benefit procurements that do not align with the code's stated scope. Seminole County, Florida issued IFB 60459723LAS seeking naloxone and safe drug deactivation systems—products entirely unrelated to motrazepam—with an electronic bid deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather market intelligence on direct-to-manufacturer prescription programs and pharmacy benefit management capabilities, an exploratory procurement mechanism with no binding commitment or award value. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802) on January 20, 2026 to establish multi-source generic pharmaceutical and over-the-counter product contracts for participating state and local facilities in Minnesota and Oregon, with responses due March 26, 2026. The code shows little relevant recent activity aligned to its nominal pharmaceutical designation and appears to be a miscoded or legacy taxonomy entry for these three opportunities.

The three opportunities span state health agencies (Texas HHS), county health departments (Seminole County), and regional cooperative purchasing bodies (MMCAP), with geographic presence in Florida, Texas, Minnesota, and Oregon. None of the solicitations target motrazepam or benzodiazepine-class pharmaceuticals specifically. The Seminole County IFB emphasizes quarterly delivery and E-Verify compliance; the Texas RFI remains exploratory and predates formal evaluation criteria; and the MMCAP RFP imposes strict manufacturing compliance (cGMP and DSCSA certification), requires relationships with at least two of three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson), and weights price competitiveness at 75 percent of evaluation. Vendors pursuing pharmaceutical procurement under this code should expect the actual scope to diverge significantly from the code name and verify the relevant commodity or family classification through direct issuing-body contact before bid preparation.